Tarsus Pharmaceuticals Inc TARS

$68.20 -3.88 (-5.38%)

Valuation

Market cap
3,362,465,000
Revenue TTM
$451,360,000
Net income TTM
$-66,420,000
PE ratio
0.00
Forward PE
—
Profit margin
-14.72%
Debt to equity
0.21

Trading

Volume
556,600
Avg volume
853,080
Day's range
$67.65 – $71.71
Shares out
49,303,000
Stochastic %K
7%
Beta
0.44
Analysts
Strong Sell
Price target
$98.56

Price

Company profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospit...

Show more

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Industry
Biotechnology
Sector
Healthcare
Phone
949 418 1801
Website
https://tarsusrx.com
Address
17700 Laguna Canyon Road, Floor 4, Irvine, United States

Latest news

Stocktwits

pineapplethebullking Oct 23, 5:21 PM
$TARS just keep buying right now!
0 replies
Creyedr Oct 21, 6:47 PM
$TARS this is heading back up, good time to add...# scripts for Xdemvy just keep rising and more providers on board daily. Last continuing education meeting, 3 of 4 lecturers talked about Lotilaner (Xdemvy) as 1st line treatment for the extremely common finding of demodex blepharitis. I have retreated many patients with demodex blepharitis with Xdemvy so it's not a one and done ... momentum will keep building.
1 replies
Hawksssss Oct 21, 4:04 AM
$TARS this company is so under the radar and so under rated. Will do 700 mil in revenue in its third year of launch. Four late stage blockbusters in pipeline all with unmet medical needs.
0 replies
making_money81 Oct 16, 1:51 PM
$TARS added 1000 shares this morning. Love this company
0 replies
ElmerFuddz Oct 15, 3:24 PM
$RXRX Go research what the CEO accomplished at $TARS. I went long today.
0 replies
Hawksssss Oct 15, 7:56 AM
$TARS if u can hold tarsus for 5 years and if all the pipeline assets are successful, u will be looking at 5 block busters with unmet medical needs. Market cap could potentially 10x. This is no joke. Just saying…
2 replies
CurrentSeaFlow Oct 13, 2:10 PM
$BMBL Saw this last night with major volume and saw the gap-up. Most bullish on this and $TARS, just from volume and float. Should have bought this last night, thought there'd be gains to be had this AM, but looks like a giant wall at 5.97.
0 replies
MadStockAlerts1 Oct 12, 1:40 PM
$YMAT $NCPL $PBR $TARS Nailing it. 🔥 our members are killing it
0 replies